{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:54:24Z","timestamp":1793120064033,"version":"4.5.0"},"reference-count":83,"publisher":"The Korean Association for the Study of the Liver","issue":"Suppl","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arbutus Biopharma"},{"name":"Assembly Biosciences"},{"DOI":"10.13039\/100002491","name":"Bristol Myer Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dicerna Pharmaceuticals"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clear B Therapeutics"},{"name":"Springbank Pharmaceuticals"},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujirebio Incorporation"},{"DOI":"10.13039\/100017981","name":"Sysmex Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017981","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ribo Life Science"}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2025,2,28]]},"abstract":"<jats:p>Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB). Nonetheless, functional cure is rarely attained with the current treatment modalities of nucleos(t)ide analogues (NUCs) and pegylated interferon alpha. Multiple novel virus-targeting agents and immunomodulators are under development for HBV with functional cure as the treatment goal. Among virus-targeting agents, antisense oligonucleotides and small-interfering RNAs are the most advanced in the developmental pipeline, and can induce potent and sustainable HBsAg suppression. The other virus-targeting agents have varying effects on HBsAg and HBV DNA, depending on the drug mechanism. In contrast, immunomodulators have modest effects on HBsAg and have limited roles in monotherapy. Multiple combination regimens incorporating RNA interference agents with immunomodulators have been studied through many ongoing clinical trials. These combination strategies demonstrate synergistic effects in inducing functional cure, and will likely be the future direction of development. Despite the promising results, research is warranted to optimize treatment protocols and to establish criteria for NUC withdrawal after novel therapies. Functional cure is now an attainable target in CHB, and the emerging novel therapeutics will revolutionize CHB management.<\/jats:p>","DOI":"10.3350\/cmh.2024.0855","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T18:25:47Z","timestamp":1731608747000},"page":"S165-181","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Prospect of emerging treatments for hepatitis B virus functional cure"],"prefix":"10.3350","volume":"31","author":[{"given":"Rex Wan-Hin","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":true,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":true,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","volume-title":""},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000431"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13095"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16728"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0399"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2196405"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.10.027"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir282"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.039"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.031"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23568"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2022.2074977"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.226"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15022892"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328380"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0448"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213429"},{"key":"ref18","first-page":"5","volume-title":"Recent advances in the development of farnesoid X receptor agonists","author":"Ali","year":"2015"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27159"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13608"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0012"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210027"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(23)00597-4"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.031"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2277389"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.07.010"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.023"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.026"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(23)03287-7"},{"key":"ref31","volume-title":"48 weeks of AB-729+nucleos(t) ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy","author":"Yuen"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333026"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-020-00523-z"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2023.05.004"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.005"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100999"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00176-x"},{"key":"ref38","first-page":"S807","volume-title":"Extended treatment of HBeAg+ CHB subjects with the Capsid assembly modulator ALG-000184 with or without Entecavir is associated with reductions in viral markers and favorable anti-HBeAb trends","author":"Yuen","year":"2024"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.12.013"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1206720"},{"key":"ref42","first-page":"684","volume-title":"Hepatitis B virus--Specific and global T-cell dysfunction in chronic hepatitis B","author":"Park","year":"2016"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.112"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.09.027"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100975"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00727-7"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.027"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12942"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(22)00538-4"},{"key":"ref50","volume-title":"HBsAg loss in chronic hepatitis B patients after 24-week treatment with subcutaneously administered PD-L1 antibody ASC22 (Envafolimab): Interim results from a phase IIb extension cohort","author":"Wang"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(20)30572-9"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31503"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.072"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13614"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.027"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100361"},{"key":"ref57","first-page":"S303","volume-title":"Reduction in hepatitis B viral DNA and hepatitis B surface antigen following administration of a single dose of VIR3434, an investigational neutralizing monoclonal antibody: First experience in a population with viremia","author":"Agarwal","year":"2022"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.09.038"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-022-00590-4"},{"key":"ref60","first-page":"790","volume-title":"Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial","author":"Yuen","year":"2023"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.046"},{"key":"ref62","first-page":"S47","volume-title":"Preliminary off-treatment responses following 48 weeks of vebicorvir, nucleos (t) ide reverse transcriptase inhibitor, and AB-729 combination in virologically suppressed patients with hepatitis B e antigen negative chronic hepatitis B: analysis from an open-label phase 2 study","author":"MacQuillan","year":"2023"},{"key":"ref63","first-page":"S811","volume-title":"VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels","author":"Tait","year":"2024"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1777639"},{"key":"ref65","first-page":"S809","volume-title":"Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment","author":"Yuen","year":"2024"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00237-1"},{"key":"ref67","first-page":"S568","volume-title":"Efficacy and safety of siRNA JNJ-73763989, capsid assembly modulator-E (CAM-E) JNJ-56136379, and nucleos (t) ide analogs (NA) with pegylated interferon alpha-2a (PEGIFN-\u03b12a) added in immune-tolerant patients with chronic hepatitis B virus (HBV) infection: interim results from the phase 2 REEF-IT study","author":"Kennedy","year":"2023"},{"key":"ref68","first-page":"S26","volume-title":"Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone","author":"Agarwal","year":"2024"},{"key":"ref69","first-page":"S79","volume-title":"Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B-interim data of the OSPREY study","author":"Bourgeois","year":"2024"},{"key":"ref70","first-page":"S36","volume-title":"Therapeutic vaccine (BRII-179) induced immune response associated with HBsAg reduction in a subset of chronic hepatitis B participants","author":"Ji","year":"2024"},{"key":"ref71","first-page":"S26","volume-title":"Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)","author":"Hou","year":"2024"},{"key":"ref72","first-page":"S27","volume-title":"A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t) ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 study","author":"Asselah","year":"2024"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(23)00488-9"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.03.006"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.03.022"},{"key":"ref76","first-page":"S807","volume-title":"High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naive B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8+ T cells in responders versus nonresponders to bepirovirsen","author":"Hogan","year":"2024"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(23)03311-1"},{"key":"ref78","first-page":"50","volume-title":"HBV DNA integration profiles in the natural history of chronic hepatitis B","author":"Hui","year":"2024"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.02.001"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.013"},{"key":"ref81","volume-title":""},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00386-7"},{"key":"ref83","first-page":"879","volume-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","year":"2023"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2024-0855.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2024.0855","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2024-0855.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T01:16:46Z","timestamp":1741828606000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2024.0855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":83,"journal-issue":{"issue":"Suppl","published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2024.0855","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2024-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-14","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}